Company Description
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies.
In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers.
It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.
The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009.
iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Martin Brenner |
Contact Details
Address: 11750 Sorrento Valley Road, Suite 200 San Diego, California 92121 United States | |
| Phone | 979 446 0027 |
| Website | ibioinc.com |
Stock Details
| Ticker Symbol | IBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001420720 |
| CUSIP Number | 451033203 |
| ISIN Number | US4510337086 |
| Employer ID | 26-2797813 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin B. Brenner D.V.M., Ph.D. | Chief Executive Officer, Chief Scientific Officer and Director |
| Felipe Duran | Chief Financial Officer |
| Marc Banjak J.D. | Chief Legal Officer |
| Kristi Sarno | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 6, 2025 | ARS | Filing |
| Oct 6, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 5, 2025 | 10-K | Annual Report |
| Sep 5, 2025 | 8-K | Current Report |
| Aug 26, 2025 | SCHEDULE 13G | Filing |
| Aug 25, 2025 | SCHEDULE 13G | Filing |
| Aug 21, 2025 | 8-K | Current Report |
| Aug 21, 2025 | 424B5 | Filing |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 18, 2025 | 424B5 | Filing |